Altschuler Steven

SEC source: 0001458116-26-000002 · form4-06292026_080651.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2036-06-24

F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.

SEC source: 0001193125-25-259056 · ownership.xml · derivative · entry 7

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 56,400 shares

Expires 2035-02-01

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]

F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4]

F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]

F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.

SEC source: 0001193125-25-259056 · ownership.xml · derivative · entry 6

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 45,150 shares

Expires 2034-02-01

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]

F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4]

F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]

F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.

SEC source: 0001193125-25-259056 · ownership.xml · derivative · entry 5

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,400 shares

Expires 2033-02-09

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]

F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4]

F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]

F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.

SEC source: 0001193125-25-259056 · ownership.xml · derivative · entry 4

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2032-05-16

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]

F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4]

F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]

F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.

SEC source: 0001193125-25-259056 · ownership.xml · derivative · entry 3

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,500 shares

Expires 2031-04-15

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]

F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4]

F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]

F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.

SEC source: 0001193125-25-259056 · ownership.xml · derivative · entry 2

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,000 shares

Expires 2030-06-22

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]

F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4]

F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]

F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.

SEC source: 0001193125-25-259056 · ownership.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2030-03-23

F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 17, 2025, by and among 89bio, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Bluefin Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On October 30, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $14.50 per Share in cash, without interest (the "Closing Amount") less any required withholding taxes, plus (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $6.00 per Share, [continues to Footnote 2]

F2 · derivative.exercise_date: [continues from Footnote 1] in cash, without interest less any required withholding taxes, upon the achievement of specified milestones on or prior to the applicable milestone outside dates, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (i) an amount in cash (without interest and subject to deduction for any required withholding taxes) equal to the product of (A) an amount equal to the excess of the Closing Amount over the exercise price per Share with respect to such Option and (B) the number of Shares subject to such Option plus (ii) one CVR with respect to each Share subject to such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Closing Amount, but less than $20.50 (any such option, an "Out of the Money Option"), [continues to Footnote 4]

F4 · derivative.exercise_date: [Continues from Footnote 3] such Out of the Money Option was not entitled to any payment of the Closing Amount in respect thereof and each Out of the Money Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Out of the Money Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (i) the number of Shares subject to such Out of the Money Option, and (ii) the amount, if any, by which (A) the Closing Amount plus the applicable milestone payment plus any other milestone payment that previously became due and payable under the terms of the CVR Agreement exceeds (B) the exercise price per Share with respect to such Out of the Money Option plus the amounts, [continues to Footnote 5]

F5 · derivative.exercise_date: [Continues from Footnote 4] if any, paid to such Option holder with respect to such CVR in respect of any milestone payments that previously became due and payable under the terms of the CVR Agreement; provided further, that any Option with an exercise price that was equal to or greater than $20.50, was cancelled immediately prior to the effective time of the Merger without the receipt of any payment of the Closing Amount or CVR in respect thereof.

SEC source: 0001415889-25-018519 · form4-06302025_050604.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-06-25

F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date.

SEC source: 0000950170-25-090483 · ownership.xml · derivative · entry 4

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,486 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 6, 2025, the Issuer and its subsidiaries (collectively, the "Debtors") filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the "Chapter 11 Cases," and such court, the "Bankruptcy Court"). On June 17, 2025, the Bankruptcy Court entered an order (the "Confirmation Order") confirming the Debtors' First Amended Joint Prepackaged Plan of Reorganization, as modified by the Confirmation Order (the "Plan"). On June 24, 2025 (the "Effective Date"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases.

F3 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of Old Common Stock upon settlement (as defined below).

F1 · kind: On May 6, 2025, the Issuer and its subsidiaries (collectively, the "Debtors") filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the "Chapter 11 Cases," and such court, the "Bankruptcy Court"). On June 17, 2025, the Bankruptcy Court entered an order (the "Confirmation Order") confirming the Debtors' First Amended Joint Prepackaged Plan of Reorganization, as modified by the Confirmation Order (the "Plan"). On June 24, 2025 (the "Effective Date"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases.

F2 · kind: Pursuant to the Plan and upon the Reporting Person ceasing to be a member of the Board of Directors, each Deferred Stock Unit settled in full.

F1 · shares: On May 6, 2025, the Issuer and its subsidiaries (collectively, the "Debtors") filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the "Chapter 11 Cases," and such court, the "Bankruptcy Court"). On June 17, 2025, the Bankruptcy Court entered an order (the "Confirmation Order") confirming the Debtors' First Amended Joint Prepackaged Plan of Reorganization, as modified by the Confirmation Order (the "Plan"). On June 24, 2025 (the "Effective Date"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases.

F2 · shares: Pursuant to the Plan and upon the Reporting Person ceasing to be a member of the Board of Directors, each Deferred Stock Unit settled in full.

F1 · price: On May 6, 2025, the Issuer and its subsidiaries (collectively, the "Debtors") filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the "Chapter 11 Cases," and such court, the "Bankruptcy Court"). On June 17, 2025, the Bankruptcy Court entered an order (the "Confirmation Order") confirming the Debtors' First Amended Joint Prepackaged Plan of Reorganization, as modified by the Confirmation Order (the "Plan"). On June 24, 2025 (the "Effective Date"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases.

F2 · price: Pursuant to the Plan and upon the Reporting Person ceasing to be a member of the Board of Directors, each Deferred Stock Unit settled in full.

F2 · derivative.exercise_date: Pursuant to the Plan and upon the Reporting Person ceasing to be a member of the Board of Directors, each Deferred Stock Unit settled in full.

F2 · derivative.expiration_date: Pursuant to the Plan and upon the Reporting Person ceasing to be a member of the Board of Directors, each Deferred Stock Unit settled in full.

SEC source: 0000950170-25-090483 · ownership.xml · nonDerivative · entry 3

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 735

F4 · shares: Pursuant to the Plan, on the Effective Date, all outstanding shares of the Issuer's common stock (the "Old Common Stock") were cancelled and extinguished. Pursuant to the Plan, new shares of the Issuer's common stock, no par value (the "New Common Stock") were issued to the Reporting Person on a ratio of 1 share of New Common Stock for approximately every 93 shares of Old Common Stock held by the Reporting Person on the Effective Date. The receipt of shares of New Common Stock was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court.

F4 · price: Pursuant to the Plan, on the Effective Date, all outstanding shares of the Issuer's common stock (the "Old Common Stock") were cancelled and extinguished. Pursuant to the Plan, new shares of the Issuer's common stock, no par value (the "New Common Stock") were issued to the Reporting Person on a ratio of 1 share of New Common Stock for approximately every 93 shares of Old Common Stock held by the Reporting Person on the Effective Date. The receipt of shares of New Common Stock was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court.

SEC source: 0000950170-25-090483 · ownership.xml · nonDerivative · entry 2

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F4 · shares: Pursuant to the Plan, on the Effective Date, all outstanding shares of the Issuer's common stock (the "Old Common Stock") were cancelled and extinguished. Pursuant to the Plan, new shares of the Issuer's common stock, no par value (the "New Common Stock") were issued to the Reporting Person on a ratio of 1 share of New Common Stock for approximately every 93 shares of Old Common Stock held by the Reporting Person on the Effective Date. The receipt of shares of New Common Stock was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court.

F4 · price: Pursuant to the Plan, on the Effective Date, all outstanding shares of the Issuer's common stock (the "Old Common Stock") were cancelled and extinguished. Pursuant to the Plan, new shares of the Issuer's common stock, no par value (the "New Common Stock") were issued to the Reporting Person on a ratio of 1 share of New Common Stock for approximately every 93 shares of Old Common Stock held by the Reporting Person on the Effective Date. The receipt of shares of New Common Stock was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court.

SEC source: 0000950170-25-090483 · ownership.xml · nonDerivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,399

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 6, 2025, the Issuer and its subsidiaries (collectively, the "Debtors") filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the "Chapter 11 Cases," and such court, the "Bankruptcy Court"). On June 17, 2025, the Bankruptcy Court entered an order (the "Confirmation Order") confirming the Debtors' First Amended Joint Prepackaged Plan of Reorganization, as modified by the Confirmation Order (the "Plan"). On June 24, 2025 (the "Effective Date"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases.

F2 · shares: Pursuant to the Plan and upon the Reporting Person ceasing to be a member of the Board of Directors, each Deferred Stock Unit settled in full.

F1 · price: On May 6, 2025, the Issuer and its subsidiaries (collectively, the "Debtors") filed voluntary petitions for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the "Chapter 11 Cases," and such court, the "Bankruptcy Court"). On June 17, 2025, the Bankruptcy Court entered an order (the "Confirmation Order") confirming the Debtors' First Amended Joint Prepackaged Plan of Reorganization, as modified by the Confirmation Order (the "Plan"). On June 24, 2025 (the "Effective Date"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases.

F2 · price: Pursuant to the Plan and upon the Reporting Person ceasing to be a member of the Board of Directors, each Deferred Stock Unit settled in full.

F3 · price: Each Deferred Stock Unit represents a right to receive one share of Old Common Stock upon settlement (as defined below).

SEC source: 0000950170-25-014433 · ownership.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,400

Underlying: Common Stock · 56,400 shares

Expires 2035-02-03

F1 · derivative.exercise_date: This option represents a right to purchase a total of 56,400 shares of the Issuer's Common Stock, which will vest in full on February 1, 2026, subject to the Reporting Person's continued service to the Issuer through such date.

SEC source: 0000950170-25-000389 · ownership.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,486

Underlying: Common Stock · 3,696 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of Common Stock upon settlement.

F2 · derivative.exercise_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock (i) for 14,784 shares, on the earlier of August 15, 2034 (at which time, such shares of Common Stock will be subject to transfer restrictions) and the date of the Reporting Person's separation from service from the Issuer's Board of Directors (the "Separation Date") and (ii) for 25,702 shares, on the Separation Date, all pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

F2 · derivative.expiration_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock (i) for 14,784 shares, on the earlier of August 15, 2034 (at which time, such shares of Common Stock will be subject to transfer restrictions) and the date of the Reporting Person's separation from service from the Issuer's Board of Directors (the "Separation Date") and (ii) for 25,702 shares, on the Separation Date, all pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

SEC source: 0000950170-24-111403 · ownership.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,790

Underlying: Common Stock · 3,696 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of Common Stock upon settlement.

F2 · derivative.exercise_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock (i) for 11,088 shares, on the earlier of August 15, 2034 (at which time, such shares of Common Stock will be subject to transfer restrictions) and the date of the Reporting Person's separation from service from the Issuer's Board of Directors (the "Separation Date") and (ii) for 25,702 shares, on the Separation Date, all pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

F2 · derivative.expiration_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock (i) for 11,088 shares, on the earlier of August 15, 2034 (at which time, such shares of Common Stock will be subject to transfer restrictions) and the date of the Reporting Person's separation from service from the Issuer's Board of Directors (the "Separation Date") and (ii) for 25,702 shares, on the Separation Date, all pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

SEC source: 0000950170-24-081572 · ownership.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,094

Underlying: Common Stock · 3,696 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of Common Stock upon settlement.

F2 · derivative.exercise_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock (i) for 7,392 shares, on the earlier of August 15, 2034 (at which time, such shares of Common Stock will be subject to transfer restrictions) and the date of the Reporting Person's separation from service from the Issuer's Board of Directors (the "Separation Date") and (ii) for 25,702 shares, on the Separation Date, all pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

F2 · derivative.expiration_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock (i) for 7,392 shares, on the earlier of August 15, 2034 (at which time, such shares of Common Stock will be subject to transfer restrictions) and the date of the Reporting Person's separation from service from the Issuer's Board of Directors (the "Separation Date") and (ii) for 25,702 shares, on the Separation Date, all pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

SEC source: 0001415889-24-018348 · form4-06272024_090634.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2034-06-24

F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of June 25, 2025, or the date of the Issuer's next annual stockholders meeting, subject to the Reporting Person's continuous service on such date.

SEC source: 0000950170-24-041132 · ownership.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,398

Underlying: Common Stock · 3,696 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of Common Stock upon settlement.

F2 · derivative.exercise_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock (i) for 3,696 shares, on the earlier of August 15, 2034 (at which time, such shares of Common Stock will be subject to transfer restrictions) and the date of the Reporting Person's separation from service from the Issuer's Board of Directors (the "Separation Date") and (ii) for 25,702 shares, on the Separation Date, all pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

F2 · derivative.expiration_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock (i) for 3,696 shares, on the earlier of August 15, 2034 (at which time, such shares of Common Stock will be subject to transfer restrictions) and the date of the Reporting Person's separation from service from the Issuer's Board of Directors (the "Separation Date") and (ii) for 25,702 shares, on the Separation Date, all pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

SEC source: 0000950170-24-011462 · ownership.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,150

Underlying: Common Stock · 45,150 shares

Expires 2034-02-01

F1 · derivative.exercise_date: This option represents a right to purchase a total of 45,150 shares of the Issuer's Common Stock, which will vest in full on February 1, 2025, subject to the Reporting Person's continued service to the Issuer through such date.

SEC source: 0000950170-24-007054 · ownership.xml · derivative · entry 2

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 105,000 shares

Expires 2033-06-13

F1 · kind: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.

F2 · derivative.exercise_date: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration ($1.60 per share) over the per share exercise price of such options, and (ii) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares.

SEC source: 0000950170-24-007054 · ownership.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 46,000 shares

Expires 2032-06-06

F1 · kind: On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.

F2 · derivative.exercise_date: Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration ($1.60 per share) over the per share exercise price of such options, and (ii) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares.

SEC source: 0000950170-24-000918 · ownership.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,702

Underlying: Common Stock · 3,696 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of Common Stock upon settlement.

F2 · derivative.exercise_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

F2 · derivative.expiration_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

SEC source: 0001209191-23-051962 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,006

Underlying: Common Stock · 3,696 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of Common Stock upon settlement.

F2 · derivative.exercise_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

F2 · derivative.expiration_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

SEC source: 0001209191-23-041064 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,310

Underlying: Common Stock · 2,053 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of Common Stock upon settlement.

F2 · derivative.exercise_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

F2 · derivative.expiration_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

SEC source: 0001209191-23-037908 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Ordinary Shares · 105,000 shares

Expires 2033-06-13

F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 14, 2024 or the date of the 2024 Annual General Meeting of the Company.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares.

SEC source: 0001209191-23-023252 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,257

Underlying: Common Stock · 2,053 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of Common Stock upon settlement.

F2 · derivative.exercise_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

F2 · derivative.expiration_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

SEC source: 0000899243-23-004826 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,400

Underlying: Common Stock · 27,400 shares

Expires 2033-02-09

F1 · derivative.exercise_date: This option represents a right to purchase a total of 27,400 shares of the Issuer's Common Stock, which will vest in full on February 9, 2024, subject to the Reporting Person's continued service to the Issuer through such date.

SEC source: 0001209191-23-000900 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,204

Underlying: Common Stock · 5,067 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of Common Stock upon settlement.

F2 · derivative.exercise_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

F2 · derivative.expiration_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

SEC source: 0001209191-22-052824 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,137

Underlying: Common Stock · 4,595 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of Common Stock upon settlement.

F2 · derivative.exercise_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

F2 · derivative.expiration_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

SEC source: 0001209191-22-041120 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,542

Underlying: Common Stock · 2,745 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of Common Stock upon settlement.

F2 · derivative.exercise_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

F2 · derivative.expiration_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

SEC source: 0001209191-22-035003 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,000

Underlying: Ordinary Shares · 46,000 shares

Expires 2032-06-06

F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 7, 2023 or the date of the 2023 Annual General Meeting of the Company.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

SEC source: 0000899243-22-018586 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-05-16

F1 · derivative.exercise_date: This option represents a right to purchase a total of 25,000 shares of the Issuer's Common Stock, which will vest in full on May 16, 2023, subject to the Reporting Person's continued service to the Issuer through such date.

SEC source: 0001209191-22-023461 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,797

Underlying: Common Stock · 1,797 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of Common Stock upon settlement.

F2 · derivative.exercise_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

F2 · derivative.expiration_date: Pursuant to the Reporting Person's election, Deferred Stock Units will be settled into shares of Common Stock on the date of the Reporting Person's separation from service from the Issuer's Board of Directors pursuant to the deferred compensation program for non-employee members of the Issuer's Board of Directors.

SEC source: 0001209191-22-001646 · doc4.xml · nonDerivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,913

F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions.

SEC source: 0001209191-21-059808 · doc4.xml · nonDerivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,734

F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions.

SEC source: 0001209191-21-045788 · doc4.xml · nonDerivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,736

F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions.

SEC source: 0001209191-21-041505 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Ordinary Shares · 40,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 16, 2022 or the date of the 2022 Annual General Meeting of the Company.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

SEC source: 0000899243-21-016224 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2031-04-15

F1 · derivative.exercise_date: This option represents a right to purchase a total of 12,500 shares of the Issuer's Common Stock, one third of which will vest on April 15, 2022, with the remaining two thirds vesting in equal monthly installments over the following two years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0001209191-21-025867 · doc4.xml · nonDerivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,213

F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions.

SEC source: 0001209191-20-039715 · doc4.xml · nonDerivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,604

F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions.

SEC source: 0000899243-20-019090 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires 2030-06-22

F1 · derivative.exercise_date: This option represents a right to purchase a total of 7,000 shares of the Issuer's Common Stock, which will vest in full on June 22, 2021, subject to the Reporting Person's continued service to the Issuer through such date.

SEC source: 0001209191-20-037901 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Ordinary Shares · 35,000 shares

Expires 2030-06-16

F1 · derivative.exercise_date: All of the shares subject to this option vest upon the earlier to occur of June 17, 2021 or the date of the 2021 Annual General Meeting of the Company.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

SEC source: 0001209191-20-022095 · doc4.xml · nonDerivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,083

F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions.

SEC source: 0000899243-20-009444 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2030-03-23

F1 · derivative.exercise_date: This option represents a right to purchase a total of 40,000 shares of the Issuer's Common Stock, which will vest in equal installments on the first, second and third anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0001209191-20-006159 · doc4.xml · derivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Ordinary Shares · 50,000 shares

Expires 2030-02-02

F1 · derivative.exercise_date: The shares subject to this option vest in equal monthly installments over the three years after February 3, 2020.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

SEC source: 0001209191-20-000246 · doc4.xml · nonDerivative · entry 1

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,955

F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions.

SEC source: 0000899243-19-029419 · doc4.xml · derivative · entry 5

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 37,203 shares

Expires 2024-08-11

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

F3 · ownership.direct: The reporting person was formerly the Chief Executive Officer of The Children's Hospital of Philadelphia Foundation ("CHOP Foundation"), and he held this option for the benefit of CHOP Foundation.

SEC source: 0000899243-19-029419 · doc4.xml · derivative · entry 4

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2026-05-31

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

SEC source: 0000899243-19-029419 · doc4.xml · derivative · entry 3

Altschuler Steven · CIK 0001458116 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,000 shares

Expires 2027-05-30

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.